🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

104+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 104 recruiting trials for “sickle-cell-beta-thalassemia-disease

NAEnrolling by InvitationNCT06300723

Clinical Study of BRL-101 in Severe SCD

👨‍⚕️ Yongrong Lai, phD, First Affiliated Hospital of Guangxi Medical University📍 1 site📅 Started Jul 2024View details ↗
NARecruitingNCT06568926

Adherence of Beta Thalssemia Patients to Oral Chelation Therapy

🏥 Sohag University📍 1 site📅 Started Jul 2024View details ↗
NARecruitingNCT06139510

Predictors of Pain in Sickle Cell Disease

👨‍⚕️ Martha Kenney, MD, Duke University📍 1 site📅 Started Jul 2024View details ↗
NARecruitingNCT06264700

Applying Directly Observed Therapy to Hydroxyurea to Realize Effectiveness

👨‍⚕️ Susan Creary, MD, MSc, Nationwide Children's Hospital📍 3 sites📅 Started Jul 2024View details ↗
RecruitingNCT06497153

Lung Ultrasound in Pediatric Acute Chest Syndrome

👨‍⚕️ Aurélie HAYOTTE, MD, Assistance Publique - Hôpitaux de Paris📍 1 site📅 Started Jun 2024View details ↗
RecruitingNCT07000747

Molecular and Cellular Basis of Severe Forms of Dengue in Sickle Cell Patients

👨‍⚕️ Maryse Etienne-Julan, MD PhD, CHU de la Guadeloupe📍 1 site📅 Started Jun 2024View details ↗
NARecruitingNCT06479616

A Long-term Follow-up Study in Participants Who Received CS-101

👨‍⚕️ Xiaowen Zhai, M.D., Children's Hospital of Fudan University📍 1 site📅 Started Jun 2024View details ↗
Enrolling by InvitationNCT06363760

A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301

🏥 Editas Medicine, Inc.📍 18 sites📅 Started Jun 2024View details ↗
NARecruitingNCT06466304

Inspiratory Muscle Training in Children With Beta Thalasemia

👨‍⚕️ hagar el-hadidy, lecturer, Faculty of Physical Therapy, Ahram Canadian University (ACU), Giza, Egypt📍 1 site📅 Started Jun 2024View details ↗
EARLY_Phase 1RecruitingNCT06313398

Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling

👨‍⚕️ John F Tisdale, M.D., National Heart, Lung, and Blood Institute (NHLBI)📍 1 site📅 Started May 2024View details ↗
Phase 1, PHASE2RecruitingNCT06308159

An Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia

🏥 Lantu Biopharma📍 2 sites📅 Started May 2024View details ↗
Phase 2RecruitingNCT06490627

Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia

🏥 National Institute of Blood and Marrow Transplant (NIBMT), Pakistan📍 1 site📅 Started Apr 2024View details ↗
Phase 1, PHASE2RecruitingNCT06280378

Β-Thalassemia Treatment with KL003 Cell Injection

👨‍⚕️ Haoquan Wu, PhD, R&D Kanglin Biotech📍 2 sites📅 Started Apr 2024View details ↗
NARecruitingNCT06035939

SMYLS Multi-site Trial

🏥 Medical University of South Carolina📍 1 site📅 Started Apr 2024View details ↗
Phase 2RecruitingNCT06358638

Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody

👨‍⚕️ Robert Nickel, MD, Children's National Research Institute📍 1 site📅 Started Apr 2024View details ↗
RecruitingNCT06073860

A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia

👨‍⚕️ Bristol-Myers Squibb, Bristol-Myers Squibb📍 2 sites📅 Started Mar 2024View details ↗
EARLY_Phase 1Enrolling by InvitationNCT06328764

CS-101 in Patients With β-thalassemia

👨‍⚕️ Yongrong Lai, M.D., First Affiliated Hospital of Guangxi Medical University📍 1 site📅 Started Mar 2024View details ↗
NARecruitingNCT06511453

Acupressure in Patients With Sickle Cell Disease

🏥 Indiana University📍 2 sites📅 Started Mar 2024View details ↗
RecruitingNCT06271512

A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel

👨‍⚕️ Himal Lal Thakar, MD, bluebird bio, Inc.📍 6 sites📅 Started Jan 2024View details ↗
Phase 1RecruitingNCT06465550

A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major

👨‍⚕️ Sujiang Zhang, M.D., Shanghai Ruijin Hospital, Shanghai Jiaotong University📍 3 sites📅 Started Jan 2024View details ↗
← PreviousPage 3 of 6Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →